Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1994 1
2005 1
2015 1
2018 1
2019 1
2020 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Changing therapeutic landscape in advanced Kaposi sarcoma: Current state and future directions.
Goff CB, Dasanu CA. Goff CB, et al. J Oncol Pharm Pract. 2023 Jun;29(4):917-926. doi: 10.1177/10781552221148417. Epub 2023 Jan 30. J Oncol Pharm Pract. 2023. PMID: 36718515 Review.
At the time of relapse, patients can be retreated with the same agents as they often maintain their clinical efficacy. New therapeutic options are on the rise, with pomalidomide being approved in 2020 as a second-line therapy. ...Clinical trials are currently underw …
At the time of relapse, patients can be retreated with the same agents as they often maintain their clinical efficacy. New therapeuti …
Evaluation of four chemotherapy regimens for treatment of advanced AIDS-associated Kaposi sarcoma in Kenya: a cost-effectiveness analysis.
Freeman EE, McCann NC, Semeere A, Reddy KP, Laker-Oketta M, Byakwaga H, Pei PP, Hajny Fernandez ME, Kiprono S, Busakhala N, Martin JN, Maurer T, Bassett IV, Freedberg KA, Hyle EP. Freeman EE, et al. Lancet Glob Health. 2022 Aug;10(8):e1179-e1188. doi: 10.1016/S2214-109X(22)00242-X. Lancet Glob Health. 2022. PMID: 35839816 Free PMC article.
METHODS: In this study, we use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International Model to project clinical outcomes and costs among people living with HIV and advanced Kaposi sarcoma on antiretroviral therapy. ...We derived …
METHODS: In this study, we use the Cost-Effectiveness of Preventing AIDS Complications (CEPAC)-International Model to project clinical …
Isolated limb perfusion is an effective treatment modality for locally advanced Kaposi sarcoma of the extremities.
Boere T, Huis In 't Veld EA, Deroose JP, van Ginhoven TM, Wouters MWJM, Grünhagen DJ, Verhoef C, van Houdt WJ. Boere T, et al. Eur J Surg Oncol. 2020 Jul;46(7):1315-1319. doi: 10.1016/j.ejso.2020.04.012. Epub 2020 Apr 14. Eur J Surg Oncol. 2020. PMID: 32359920
MATERIAL AND METHODS: All patients who underwent ILP for KS between 1996 and 2018 at Erasmus MC, Rotterdam were identified. Clinical data was obtained from either a prospectively maintained database or retrospective assessment of patient files. ...
MATERIAL AND METHODS: All patients who underwent ILP for KS between 1996 and 2018 at Erasmus MC, Rotterdam were identified. Clinical …
A Pilot Study of Liposomal Doxorubicin Combined with Bevacizumab followed by Bevacizumab Monotherapy in Patients with Advanced Kaposi Sarcoma.
Ramaswami R, Uldrick TS, Polizzotto MN, Wyvill KM, Goncalves P, Widell A, Lurain K, Steinberg SM, Figg WD, Tosato G, Whitby D, Yarchoan R. Ramaswami R, et al. Clin Cancer Res. 2019 Jul 15;25(14):4238-4247. doi: 10.1158/1078-0432.CCR-18-3528. Epub 2019 Apr 12. Clin Cancer Res. 2019. PMID: 30979736 Free PMC article.
RESULTS: Sixteen patients were enrolled: 10 (two HIV negative) in cohort 1 and six in cohort 2. Fourteen patients had advanced disease (AIDS Clinical Trials Group T(1)). Overall response rate (complete and partial responses) was 56% [80% confidence interval (CI), 38%-74%] …
RESULTS: Sixteen patients were enrolled: 10 (two HIV negative) in cohort 1 and six in cohort 2. Fourteen patients had advanced disease (AIDS …
Plasma biomarkers of clinical response during chemotherapy plus combination antiretroviral therapy (cART) in HIV+ patients with advanced Kaposi sarcoma.
Tedeschi R, Bidoli E, Bortolin MT, Schioppa O, Vaccher E, De Paoli P. Tedeschi R, et al. Oncotarget. 2015 Oct 6;6(30):30334-42. doi: 10.18632/oncotarget.4571. Oncotarget. 2015. PMID: 26296972 Free PMC article.
This study aimed to evaluate plasma concentration of selected cancer-associated inflammatory and immune-modulated cytokines in HIV+ patients with advanced Kaposi sarcoma (KS), and to explore candidate biomarkers capable of predicting clinical outcome i …
This study aimed to evaluate plasma concentration of selected cancer-associated inflammatory and immune-modulated cytokines in HIV+ patients …
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M, Huitema AD, Meenhorst PL, Schellens JH, Beijnen JH. Joerger M, et al. Cancer Chemother Pharmacol. 2005 May;55(5):488-96. doi: 10.1007/s00280-004-0900-4. Epub 2005 Feb 23. Cancer Chemother Pharmacol. 2005. PMID: 15726371 Clinical Trial.
PURPOSE: Systemic chemotherapy is the treatment of choice for AIDS-related advanced Kaposi sarcoma. One principal schedule combines adriamycin (doxorubicin), bleomycin, and vincristine (ABV). ...MATERIALS AND METHODS: A previously described high-performance l …
PURPOSE: Systemic chemotherapy is the treatment of choice for AIDS-related advanced Kaposi sarcoma. One principal sched …
Omega-3 decreases IL-6 levels in HIV and human herpesvirus-8 coinfected patients in Uganda.
Coghill AE, Schenk JM, Mahkoul Z, Orem J, Phipps W, Casper C. Coghill AE, et al. AIDS. 2018 Feb 20;32(4):505-512. doi: 10.1097/QAD.0000000000001722. AIDS. 2018. PMID: 29381560 Free PMC article. Clinical Trial.
Patients with acute illness, AIDS, or advanced Kaposi sarcoma were ineligible, as were pregnant women. Participant IDs were pre-randomized, blocked by Kaposi sarcoma status, to either the omega-3 or placebo arm. ...CONCLUSION: Omega-3 supplementation d …
Patients with acute illness, AIDS, or advanced Kaposi sarcoma were ineligible, as were pregnant women. Participant IDs …
Liposomal doxorubicin in the treatment of advanced AIDS-related Kaposi sarcoma.
Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD. Bogner JR, et al. J Acquir Immune Defic Syndr (1988). 1994 May;7(5):463-8. J Acquir Immune Defic Syndr (1988). 1994. PMID: 8158540 Clinical Trial.
Neither single-agent therapy nor any combination treatment has been satisfactory enough to be regarded as standard in systemic advanced Kaposi sarcoma. In an attempt to achieve high efficacy in combination with low toxicity, we used a new liposomal formulatio …
Neither single-agent therapy nor any combination treatment has been satisfactory enough to be regarded as standard in systemic advanced …
Chemotherapy for advanced Kaposi sarcoma.
Lanzotti VJ, Campos LT, Sinkovics JG, Samuels ML. Lanzotti VJ, et al. Arch Dermatol. 1975 Oct;111(10):1331-3. Arch Dermatol. 1975. PMID: 53034
However, prognosis is serious for patients with aggressive cutaneous disease, and aminous for those with visceral involvement. Two cases of advanced Kaposi sarcoma are reviewed to illustrate a chemotherapeutic approach to patients with this disease. ...
However, prognosis is serious for patients with aggressive cutaneous disease, and aminous for those with visceral involvement. Two cases of …